• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » FDA Enforcement of Clinical Trial Violations Declining Under Trump

FDA Enforcement of Clinical Trial Violations Declining Under Trump

October 5, 2020

The FDA has been slacking off on enforcement of clinical trial regulations, according to a recent investigation of the agency’s inspection statistics that shows a substantial drop in serious citations in the first three years of the Trump administration.

Since 2009, the FDA has conducted about 6,700 inspections of clinical investigators and IRBs, issuing the strongest citation, “Official Action Indicated” (OAI) in only 291 cases (4 percent) for serious, illegal and potentially dangerous clinical trial infractions.

But in the first three years of the Trump administration, that number dropped to 1 percent. In comparison, the eight years of the Obama presidency saw the agency issue OAI citations in about 6 percent of cases, an article in the October issue of Science magazine points out.

The article’s authors examined 1,600 FDA inspection and enforcement documents issued since 2009, including warning letters and investigator debarment notices, concluding the agency’s regulatory enforcement has become “lax, slow-moving and secretive.”

The number of warning letters issued to investigators and IRBs also dropped dramatically during the first three years of the Trump presidency. The FDA issued only 12 warning letters from 2017 to 2019, while President Obama’s FDA issued 99 from 2009 to 2011, the first three years of his first term, and 36 from 2014 to 2016, the last three years of his second term.

Warning letters in Obama’s first term resulted in seven trial and IRB shutdowns and restrictions, but the Trump administration has not followed through with enforcement action on any of its 12 cases.

Noncompliant investigators also got off light under Trump; only two were barred from participating in future FDA-regulated trials. The FDA barred an average of three investigators per year — mostly for data falsification — under President Obama.

The FDA did not dispute the figures in the Science article and said that Trump administration policies were not a factor. “The number of warning letters can ebb and flow,” the agency wrote in an email.

The reporting of the story was funded by Science’s Fund for Investigative Journalism.

Upcoming Events

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing